[BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
BCG intravesical instillation is a well established therapy for superficial bladder carcinoma as adjuvant and/or prophylactic treatment. However side-effects are frequent when full doses are employed and therefore low dose alternative schedules were proposed. Interferon intraluminal therapy for bladder TCC has been used with similar indication but the results did not encourage further single drug trials. A double arm random study, BCG full dose vs. BCG low dose, is presented. The results point out that the combination treatment is superior to BCG full dose therapy in terms of side effects and similar to BCG full dose as regards efficiency (5/18 vs 4/18 recurrences) after a follow-up of 24.11 +/- 8.15 for BCG and 16.72 +/- 8.7 for BCG + IFN.
Bercovich
E
E
Istituto di Clinica Urologica, Università di Sassari.
Deriu
M
M
Manferrari
F
F
Irianni
G
G
D000283:Administration, Intravesical; D000368:Aged; D001500:BCG Vaccine / Q000008:administration & dosage*; D002277:Carcinoma / Q000628:therapy*; D003627:Data Interpretation, Statistical; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control; D011994:Recombinant Proteins; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins
BCG vs. BCG plus alpha-interferon 2b ricombinante nei tumori superficiali della vescica.